Weave Bio alternatives for regulatory submissions in 2026
Weave Bio is an AI platform for drafting, verifying and assembling regulatory submissions. Teams look at alternatives when they want one platform that also covers quality, clinical and regulatory research, when their documents already live in SharePoint or Veeva, or when they want to see an open benchmark before they buy.
Arca covers all three. This page compares Weave with Arca and four other tools, using what each vendor says about itself on its own site in November 2026.
About Weave Bio
Weave describes itself as an AI-native platform for drug development teams. It has two products today, Submission Builder and HAQ Manager, and says a third, Program Planner, launches in the fourth quarter of 2026.
- Submission Builder drafts content across Modules 1, 2, 3 and 5 inside an eCTD structure. It traces claims to sources sentence by sentence, runs automated reviews for inconsistencies and exports finished content as DOCX.
- HAQ Manager takes in health authority questions, tracks who owns each one and generates responses.
- Weave says it has completed 12 FDA submissions and cut submission timelines by 60%. In a study with Takeda, it reports turning about 100 hours of IND nonclinical written summaries into 2.6 to 3.7 hours.
- It lists SOC 2, SAML-compatible single sign-on and zero data retention with its LLM providers. It exports completed documents to Veeva.
Weave is a strong fit for a team whose main job is assembling one eCTD dossier and working through agency questions.
The alternatives
| Tool | Built for | What the vendor says |
|---|---|---|
| Arca | Regulatory, quality and clinical teams that want research, drafting and review on their own documents | Agents that draft from your Veeva, SharePoint and Google Drive files, with each claim linked to its source |
| Bluenote | Documentation across nonclinical, clinical, CMC, regulatory and quality | Agentic AI platform that it says speeds documentation by 75%, with SOC 2 Type II and an on-premise option |
| Peer AI | Clinical and regulatory documents: CSRs, protocols, INDs, investigator's brochures | Authoring plus a Command Center for program status and prediction of likely agency queries |
| Certara CoAuthor | Regulatory writers who work in Microsoft Word | Generative AI, structured content and more than 275 eCTD templates inside Word |
| Veeva | Teams already on Vault RIM | RIM that "unifies regulatory systems and processes on a single cloud platform to enable end-to-end submission and registration management" |
Arca and Weave side by side
| Weave Bio | Arca | |
|---|---|---|
| Scope | Submission authoring, health authority questions, program planning | Regulatory submissions, quality documents, clinical documents, regulatory intelligence and MLR review |
| Where people work | Weave's editor, DOCX export | Arca on the web, Arca in Microsoft Word, and Slack, Teams or email |
| Source systems | Imports source documents and exports to Veeva | Reads Veeva Vault, SharePoint, Google Drive, OneDrive and Box |
| Reusable work | Configurable AI templates | AOPs, automated operating procedures written from your own SOPs |
| Dossier structure | eCTD structure for Modules 1, 2, 3 and 5 | Dossier outlines for CMC Module 3, IND and NDA/BLA, plus gap analysis against them |
| Sources beyond your files | Literature citations | More than 250 public sources, including FDA, EMA, ICH and PubMed |
| Models | Zero data retention with its LLM providers | Routes each request to the model that fits and publishes scores for several models |
| Security | SOC 2, SAML-compatible SSO | SOC 2 Type II, GDPR, SAML SSO; evidence at trust.arca.inc |
| Published evidence | 12 FDA submissions, 60% faster timelines, a Takeda study | LifeSci Diamond, an open benchmark of 55 regulatory affairs tasks |
The two platforms overlap on drafting with source tracing. They diverge in how far the platform reaches. A team on Arca can draft a Module 3 section, check it against a gap analysis, assess a post-approval change, answer an information request in Word and research a guidance question without leaving one platform.
What the open benchmark shows
Arca published LifeSci Diamond, 55 regulatory affairs tasks written with practising regulatory specialists, with the harness and ten example tasks on GitHub. On it, Arca running GPT-6 Astra passes 29.1% of tasks strictly, against 20.0% for the same model's plain API. Arca's Auto setting, which picks a model for each request, passes 20.0% at $0.15 per task. Over 30 days, model routing cut customers' AI costs by 76%.
Weave's published results come from its own customers and a study with Takeda. Neither vendor has run the other on a shared benchmark.
For a wider comparison by job (authoring, publishing, agency questions), see AI regulatory submission software compared.
Choosing
Choose Weave if your work is one eCTD dossier and its agency questions. Choose Veeva if your team already runs Vault RIM and wants AI inside it. Choose CoAuthor if your writers want to stay in Word with a template library. Choose Bluenote or Peer AI for clinical and regulatory documentation with a specialist authoring tool.
Choose Arca if you want regulatory, quality, clinical and research work on the same documents, with your existing Veeva, SharePoint and Word workflow intact.
Frequently asked questions
What is the best alternative to Weave Bio?
It depends on the job. Arca fits teams that want regulatory, quality and clinical work on one platform and their own document systems connected. Bluenote and Peer AI focus on documentation, and Certara CoAuthor runs inside Word.
Does Arca work with Veeva?
Yes. Arca reads from Veeva Vault and drafts in your own templates. It also reads SharePoint, Google Drive, OneDrive and Box.
Can Arca draft an IND or NDA?
Yes. Arca has dossier outlines for CMC Module 3, IND and NDA/BLA, drafts from your source documents and links each claim to where it came from. A person reviews and approves the result.
Has Weave Bio been tested against Arca?
No shared benchmark exists. Arca's results are on LifeSci Diamond, and Weave reports results from its own customers.